Itokazu M, Kumazawa S, Wada E, Wenyi Y
Department of Orthopaedic Surgery, Gifu University School of Medicine, Japan.
Cancer Lett. 1996 Oct 1;107(1):11-8. doi: 10.1016/0304-3835(96)04337-6.
A sustained-release drug delivery system was developed using a hydroxyapatite (HA) block loaded with adriamycin (ADR) by cenrifugation. Release of ADR was sustained for 66 days in vitro and for 4 weeks in vivo following intramuscular implantation in mice. ADR concentrations in plasma, liver, and kidney were from 0.25% to 10% of that at the implantation site. ADR-HA blocks implanted into osteogenic sarcomas in mice markedly inhibited tumor growth. This drug delivery system provides sustained release of the cancer chemotherapeutic agent and may prove useful for treating malignant tumours while minimising systemic side effects.
通过离心法制备了一种载有阿霉素（ADR）的羟基磷灰石（HA）块体缓释药物递送系统。阿霉素在体外可持续释放66天，在小鼠肌肉内植入后在体内可持续释放4周。血浆、肝脏和肾脏中的阿霉素浓度为植入部位浓度的0.25%至10%。植入小鼠骨肉瘤中的阿霉素-羟基磷灰石块体显著抑制肿瘤生长。这种药物递送系统可实现癌症化疗药物的持续释放，可能对治疗恶性肿瘤有用，同时将全身副作用降至最低。
